TWI623531B - 經取代反向嘧啶ｂｍｉ－１抑制劑 - Google Patents

經取代反向嘧啶ｂｍｉ－１抑制劑 Download PDF

Info

Publication number
TWI623531B
TWI623531B TW102142555A TW102142555A TWI623531B TW I623531 B TWI623531 B TW I623531B TW 102142555 A TW102142555 A TW 102142555A TW 102142555 A TW102142555 A TW 102142555A TW I623531 B TWI623531 B TW I623531B
Authority
TW
Taiwan
Prior art keywords
diamine
pyrimidine
fluoro
benzimidazol
methyl
Prior art date
Application number
TW102142555A
Other languages
English (en)
Chinese (zh)
Other versions
TW201427972A (zh
Inventor
李昌宣
Chang-Sun Lee
瑞米爾 拜亞茲托夫
Ramil BAIAZITOV
曹良山
Liangxian Cao
湯瑪士Ｗ 戴維斯
Thomas W. Davis
杜武
Wu Du
劉瑞根
Ronggang Liu
文榮春
Young-Choon Moon
史帝文Ｄ 派吉特
Steven D. Paget
任洪玉
Hongyu Ren
那迪亞 席德倫可
Nadiya Sydorenko
理查 傑拉德 威德
Richard Gerald Wilde
Original Assignee
Ｐｔｃ治療公司
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ｐｔｃ治療公司, Ptc Therapeutics, Inc. filed Critical Ｐｔｃ治療公司
Publication of TW201427972A publication Critical patent/TW201427972A/zh
Application granted granted Critical
Publication of TWI623531B publication Critical patent/TWI623531B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
TW102142555A 2012-11-21 2013-11-21 經取代反向嘧啶ｂｍｉ－１抑制劑 TWI623531B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
US61/728,907 2012-11-21

Publications (2)

Publication Number Publication Date
TW201427972A TW201427972A (zh) 2014-07-16
TWI623531B true TWI623531B (zh) 2018-05-11

Family

ID=50776672

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102142555A TWI623531B (zh) 2012-11-21 2013-11-21 經取代反向嘧啶ｂｍｉ－１抑制劑

Country Status (32)

Country Link
US (3) US10428050B2 (enExample)
EP (1) EP2922828B1 (enExample)
JP (3) JP6412503B2 (enExample)
KR (4) KR102356487B1 (enExample)
CN (2) CN111423417B (enExample)
AR (1) AR093579A1 (enExample)
AU (1) AU2013348009C1 (enExample)
BR (1) BR112015011760B1 (enExample)
CA (1) CA2892045C (enExample)
CL (1) CL2015001377A1 (enExample)
CR (1) CR20150294A (enExample)
CU (1) CU24387B1 (enExample)
DK (1) DK2922828T3 (enExample)
EA (2) EA035349B1 (enExample)
EC (1) ECSP15019948A (enExample)
ES (1) ES2821529T3 (enExample)
HK (1) HK1215032A1 (enExample)
IL (2) IL238871B (enExample)
MA (1) MA38208B1 (enExample)
MX (2) MX385385B (enExample)
NI (1) NI201500072A (enExample)
NZ (2) NZ708909A (enExample)
PE (1) PE20151413A1 (enExample)
PH (1) PH12015501130B1 (enExample)
PL (1) PL2922828T3 (enExample)
PT (1) PT2922828T (enExample)
SA (1) SA517381847B1 (enExample)
SG (2) SG10201600149VA (enExample)
TW (1) TWI623531B (enExample)
UA (1) UA118094C2 (enExample)
WO (1) WO2014081906A2 (enExample)
ZA (1) ZA201503642B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12015501130B1 (en) 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) * 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
MX370588B (es) * 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
ES3067417T3 (en) 2015-08-11 2026-05-21 Cognoa Inc Apparatus to determine developmental progress with artificial intelligence and user input
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
WO2017123826A1 (en) * 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN118609834A (zh) 2016-11-14 2024-09-06 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
JP7324709B2 (ja) * 2017-02-09 2023-08-10 コグノア，インク． デジタル個別化医療のためのプラットフォームとシステム
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
JP2021535198A (ja) * 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
WO2020150326A1 (en) * 2019-01-15 2020-07-23 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
AU2020227748A1 (en) * 2019-02-28 2021-09-16 Ptc Therapeutics, Inc. Method for treating a multiple myeloma
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형
CN113873935B (zh) 2019-03-22 2024-11-22 科格诺亚公司 个性化数字化治疗方法和装置
CA3134648A1 (en) * 2019-03-27 2020-10-01 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
US20220177459A1 (en) * 2019-04-02 2022-06-09 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
WO2021046412A1 (en) 2019-09-06 2021-03-11 Cognoa, Inc. Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20260188467A1 (en) * 2024-12-27 2026-07-02 Center for Social Dynamics, LLC Parallel Processing Systems and Methods For Real-Time Multimodal Behavioral Classification Using Neural Networks With Dynamic Content Adaptation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110190239A1 (en) * 2008-07-01 2011-08-04 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
EP0775120B1 (en) * 1994-08-13 2003-06-04 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
IN188411B (enExample) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
ATE311385T1 (de) 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
KR20030024659A (ko) * 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1330452T3 (da) 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
EP1377573B1 (en) 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
BR0207096A (pt) 2001-02-20 2004-01-20 Astrazeneca Ab Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
CA2452603A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) * 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
ATE457025T1 (de) 2002-05-23 2010-02-15 Cytopia Res Pty Ltd Kinaseinhibitoren
CN100343237C (zh) 2002-06-28 2007-10-17 日本新药株式会社 酰胺衍生物及医药品
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
US7060850B2 (en) * 2002-07-11 2006-06-13 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004035588A1 (en) 2002-10-15 2004-04-29 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
WO2005076854A2 (en) 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
BRPI0607062A2 (pt) 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
EP1858882A1 (en) 2005-03-10 2007-11-28 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
JP2010505794A (ja) * 2006-10-03 2010-02-25 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤として有用なインダゾリル誘導体
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
PE20081636A1 (es) 2007-01-26 2009-01-10 Smithkline Beecham Corp Inhibidores de antranilamida para aurora quinasa
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
EP2231636B1 (en) 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
EP2331527A1 (en) 2008-09-02 2011-06-15 NeuroSearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
EP2397479A4 (en) 2009-02-12 2012-08-01 Astellas Pharma Inc HETERO RING DERIVATIVE
CA2756067A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2435435B1 (en) 2009-05-27 2014-01-29 AbbVie Inc. Pyrimidine inhibitors of kinase activity
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
GEP20207129B (en) * 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
CN102471345A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
CN102812022B (zh) 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
KR101788903B1 (ko) * 2010-08-19 2017-10-23 에프. 호프만-라 로슈 아게 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환
DK2616465T3 (da) 2010-09-13 2016-02-01 Novartis Ag Triazin-oxadiazoler
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
JP2014500277A (ja) 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
ES2587304T3 (es) 2011-02-25 2016-10-21 Yuhan Corporation Derivados de diaminopirimidina y procedimientos para la preparación de los mismos
ES2698847T3 (es) * 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
PH12015501130B1 (en) * 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110190239A1 (en) * 2008-07-01 2011-08-04 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators

Also Published As

Publication number Publication date
NZ708909A (en) 2019-11-29
CA2892045C (en) 2022-05-31
US11180483B2 (en) 2021-11-23
IL265253A (en) 2019-05-30
UA118094C2 (uk) 2018-11-26
ZA201503642B (en) 2020-10-28
EA031405B1 (ru) 2018-12-28
BR112015011760A2 (pt) 2017-07-11
JP6918898B2 (ja) 2021-08-11
KR20150086345A (ko) 2015-07-27
US20150315182A1 (en) 2015-11-05
AU2013348009C1 (en) 2019-08-08
SG10201600149VA (en) 2016-02-26
CN111423417B (zh) 2022-11-15
PL2922828T3 (pl) 2020-12-28
PH12015501130A1 (en) 2015-08-03
NZ746607A (en) 2019-11-29
TW201427972A (zh) 2014-07-16
AU2013348009A1 (en) 2015-06-04
CN104918919A (zh) 2015-09-16
PH12015501130B1 (en) 2023-01-27
KR102356487B1 (ko) 2022-02-08
JP2020055815A (ja) 2020-04-09
IL238871B (en) 2019-03-31
KR102455889B1 (ko) 2022-10-17
NI201500072A (es) 2016-01-18
MX2015006469A (es) 2015-10-29
JP6412503B2 (ja) 2018-10-24
JP6617186B2 (ja) 2019-12-11
KR20220143164A (ko) 2022-10-24
JP2019031509A (ja) 2019-02-28
KR102275676B1 (ko) 2021-07-12
IL238871A0 (en) 2015-07-30
CN111423417A (zh) 2020-07-17
JP2016504290A (ja) 2016-02-12
EP2922828B1 (en) 2020-07-08
DK2922828T3 (da) 2020-08-31
ES2821529T3 (es) 2021-04-26
CR20150294A (es) 2015-08-20
AU2013348009B2 (en) 2018-05-17
AR093579A1 (es) 2015-06-10
MX385385B (es) 2025-03-18
KR20210088740A (ko) 2021-07-14
KR20220016305A (ko) 2022-02-08
CL2015001377A1 (es) 2016-02-19
MX2021009892A (es) 2021-09-14
US10428050B2 (en) 2019-10-01
EP2922828A2 (en) 2015-09-30
CU24387B1 (es) 2019-03-04
EA035349B1 (ru) 2020-05-29
HK1215032A1 (zh) 2016-08-12
PE20151413A1 (es) 2015-10-23
US20200024260A1 (en) 2020-01-23
WO2014081906A3 (en) 2014-07-17
PT2922828T (pt) 2020-10-12
SG11201503982XA (en) 2015-06-29
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (en) 2014-05-30
US20220064150A1 (en) 2022-03-03
CA2892045A1 (en) 2014-05-30
MA38208B1 (fr) 2021-12-31
CU20150053A7 (es) 2015-11-27
EP2922828A4 (en) 2016-07-27
EA201590992A1 (ru) 2015-11-30
EA201890142A1 (ru) 2018-06-29
ECSP15019948A (es) 2016-01-29
BR112015011760B1 (pt) 2022-12-06

Similar Documents

Publication Publication Date Title
JP6918898B2 (ja) 置換逆ピリミジンＢｍｉ−１阻害剤
TWI692477B (zh) 經取代嘧啶ｂｍｉ-１抑制劑
US9975878B2 (en) Substituted triazine BMI-1 inhibitors
HK40034027B (en) Substituted reverse pyrimidine bmi-1 inhibitors
HK1226057B (en) Substituted pyrimidine bmi-1 inhibitors
BR112016004511B1 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees